Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on CytomX Therapeutics (NASDAQ:CTMX) Inc on Thursday, setting a price target of $16, which is approximately 37.93% above the present share price of $11.6.
Goldstein expects CytomX Therapeutics Inc to post earnings per share (EPS) of -$0.79 for the second quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in CytomX Therapeutics, with an average price target of $12.83.
The analysts price targets range from a high of $16 to a low of $7.
In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $8.28 million and a net profit of -$37.38 million. The company's market cap is $553.37 million.
According to TipRanks.com, Mizuho Securities analyst Mara Goldstein is a 1-star analyst with an average return of -0.7% and a 34.6% success rate.
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.